NCT02136017

Brief Summary

To evaluate the safety of the post-licensed influenza virus vaccine made of Changchun Institute of Biological Products Co.,Ltd.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2013

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 8, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 12, 2014

Completed
Last Updated

May 12, 2014

Status Verified

May 1, 2014

Enrollment Period

11 months

First QC Date

May 8, 2014

Last Update Submit

May 8, 2014

Conditions

Keywords

AEFIinfluenza vaccine

Outcome Measures

Primary Outcomes (1)

  • occurence rate of adverse reaction

    the general or local reactions are reported after vaccination .

    1 month after vaccination

Study Arms (1)

Changchun biologial's vaccine

Changchun Biological's vaccine group is the population injected with this vaccine.

Eligibility Criteria

Age3 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all the people immunized by influenza vaccine of Changchun Institute of Biological Product in Sichuan province in 2013.

You may qualify if:

  • ever vaccinated one dose influenza vaccine(manufactured by Changchun institute of biological product) in 2013
  • above 3 years old

You may not qualify if:

  • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any IIV or LAIV
  • allergic to a vaccine component, including egg protein.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Influenza, HumanDrug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract DiseasesChemically-Induced Disorders

Study Officials

  • rui ao, master

    Sichuan CDC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 8, 2014

First Posted

May 12, 2014

Study Start

January 1, 2013

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

May 12, 2014

Record last verified: 2014-05